Pradžia › Amiloidozė › Tennessee
Amiloidozė klinikiniai tyrimai Tennessee
7 tyrimai dėl Amiloidozė ieško dalyvių vietose Tennessee.
Miestai Tennessee
Oficialus tyrimo tekstas (anglų kalba)
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- Research Site, Germantown
- Research Site, Nashville
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 130 · Visoms lytims · Atnaujinta 2026-09-23 · NCT06465810TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Clinical Trial Site, Nashville
Renkami dalyviai3 fazė
Amžius nuo 18 iki 85 · Visoms lytims · Atnaujinta 2026-09-15 · NCT07223203DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
- Clinical Trial Site, Memphis
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-09 · NCT07358078Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
- Vanderbilt Ingram Cancer Center, Nashville
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-19 · NCT05145816A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
- University of Tennessee Graduate School of Medicine, Knoxville
Renkami dalyviai1 fazėLaukiami sveiki savanoriai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-24 · NCT05951816A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
- Research Site, Nashville
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-02 · NCT07081646A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
- Vanderbilt University Medical Center. /ID# 273510, Nashville
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-13 · NCT06158854Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.